Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of head and neck cancer~  * No clinical evidence of disease recurrence by ear, nose, and throat exam with a nasopharyngeal scope, if indicated, 8 weeks prior to registration~* Completed radiotherapy (i.e., standard or intensity-modulated radiotherapy) with or without chemotherapy ≥ 3 months and up to 2 years prior to study entry~  * Grade 1-2 radiotherapy-induced xerostomia according to the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.3.0 and the dry mouth/salivary gland xerostomia scale~ * Must have evidence of residual salivary function with unstimulated (basal) whole salivary production ≥ 0.1 ml/min after having refrained from eating or drinking oral fluid for 2 hours~* No patients with normal saliva production (i.e., no salivary gland changes or no xerostomia)~* No history of serious adverse events after prior treatment with and discontinuation of pilocarpine~* No chronic lymphocytic leukemia~PATIENT CHARACTERISTICS:~* See Disease Characteristics~* Zubrod performance status of 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other invasive malignancy except non-melanomatous skin cancer or cancer from which the patient has been disease-free for at least 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix)~* No concurrent contraindications to pilocarpine (e.g., uncontrolled asthma, miosis, or hypersensitivity)~* No severe, active co-morbidity, including any of the following:~  * Unstable cardiac disease or requirement for a pacemaker in-situ~ * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~ * Transmural myocardial infarction within the past 6 months~ * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration~ * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects~* No Sjögren syndrome~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior pilocarpine or cevimeline and no concurrent use for ophthalmic or non-ophthalmic indications~* No concurrent regular medications that induce xerostomia (e.g., tricyclic antidepressants, antihistamines with anticholinergic effects, or narcotics)~* No concurrent oral stimulating agents or salivary gland medical stimulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pilocarpine: Phase III (Type: ACTIVE_COMPARATOR): None
- ALTENS: Phase III (Type: EXPERIMENTAL): None
- ALTENS: Phase II (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete